SAVA Key Statistics, Chart & Performance
The current stock price of SAVA is 3.25 USD. In the past month the price decreased by -0.91%. In the past year, price decreased by -15.36%.
SAVA Latest News, Press Relases and Analysis
SAVA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.91 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.53B | ||
| MRK | MERCK & CO. INC. | 11.9 | 260.19B | ||
| PFE | PFIZER INC | 8.04 | 146.35B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.16B | ||
| ZTS | ZOETIS INC | 20.22 | 56.49B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.74 | 23.10B | ||
| VTRS | VIATRIS INC | 4.59 | 12.31B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.24 | 11.56B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.64B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.80B |
Related stock screener links
About SAVA
Company Profile
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 30 full-time employees. The company went IPO on 2000-07-14. The firm's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. The company has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Company Info
CASSAVA SCIENCES INC
6801 N. Capital of Texas Highway, Building 1
Austin TEXAS 78731 US
CEO: Remi Barbier
Employees: 30
Phone: 15125012444
CASSAVA SCIENCES INC / SAVA FAQ
What does CASSAVA SCIENCES INC do?
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 30 full-time employees. The company went IPO on 2000-07-14. The firm's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. The company has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
Can you provide the latest stock price for CASSAVA SCIENCES INC?
The current stock price of SAVA is 3.25 USD. The price decreased by -4.13% in the last trading session.
Does SAVA stock pay dividends?
SAVA does not pay a dividend.
How is the ChartMill rating for CASSAVA SCIENCES INC?
SAVA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is SAVA stock listed?
SAVA stock is listed on the Nasdaq exchange.
What is the employee count for SAVA stock?
CASSAVA SCIENCES INC (SAVA) currently has 30 employees.
When does CASSAVA SCIENCES INC (SAVA) report earnings?
CASSAVA SCIENCES INC (SAVA) will report earnings on 2026-03-02, after the market close.
SAVA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SAVA. When comparing the yearly performance of all stocks, SAVA is one of the better performing stocks in the market, outperforming 78.95% of all stocks.
SAVA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SAVA. The financial health of SAVA is average, but there are quite some concerns on its profitability.
SAVA Financial Highlights
Over the last trailing twelve months SAVA reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS increased by 37.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -81.73% | ||
| ROE | -129.99% | ||
| Debt/Equity | 0 |
SAVA Forecast & Estimates
8 analysts have analysed SAVA and the average price target is 5.1 USD. This implies a price increase of 56.92% is expected in the next year compared to the current price of 3.25.